• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

ASCRS names Stephen H. Speares executive director

Article

The American Society of Cataract and Refractive Surgery’s (ASCRS) Executive Committee announced that Stephen H. “Steve” Speares will serve as the society’s next executive director, according to a prepared statement.

The American Society of Cataract and Refractive Surgery’s (ASCRS) Executive Committee announced that Stephen H. “Steve” Speares will serve as the society’s next executive director, according to a prepared statement.

Speares replaces David Karcher, who retired after leading ASCRS for 38 years.

“Steve’s breadth of experience, excellent leadership skills, solid understanding of ophthalmology and pioneering spirit will take ASCRS to new heights,” said Karcher in the statement.

“I am excited to lead ASCRS and build on Dave’s incredible track record of leadership, dedication to ophthalmology and unwavering commitment to those in the profession,” said Speares in the statement. 

“As we move into this new era, I look forward to leveraging the society’s founding vision, rooted in innovation, to identify new opportunities to increase the value ASCRS brings to anterior segment surgeons, and the patients they serve,” he said.

Speares, who is currently vice president, Europe and Middle East at Glaukos, will formally begin his role in April 2018, at the ASCRS annual meeting in Washington, DC. Previously, he worked at Alcon Laboratories, where he held a variety of operational positions during his 18 years there.

Karcher will stay on in an advisory role to the association until the transition is complete.

 

 

 

 

Related Videos
Video 6 - "Impact Of Durable Agents on Treatment Burden and Quality of Life in Retinal Diseases"
Video 5 - "Evolving Role of Steroids and Laser In DME"
Video 4 - "A Case of a DME Patient Achieving Extended Treatment Interval with New Therapy"
Video 3 - "Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent"
Video 2 - "A Case of Neovascular AMD with Persistent Subretinal Fluid"
Video 1 - "A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment"
Video 1 - "Challenging the Definition of Dry Eye- Interpreting Diagnostic Tests"
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
© 2024 MJH Life Sciences

All rights reserved.